NCT05790889 is a Phase 1, PHASE2 clinical trial of Rabies vaccine in Malaria,Falciparum, sponsored by University of Oxford.

Who is sponsoring NCT05790889?

NCT05790889 is sponsored by University of Oxford.

What drugs are being tested in NCT05790889?

Interventions in NCT05790889: Rabies vaccine, RH5.1 10μg adjuvated with 50μg Matrix-M, RH5.2 5μg adjuvated with 50μg Matrix-M.

What condition does NCT05790889 study?

NCT05790889 studies Malaria,Falciparum.

Is NCT05790889 still recruiting?

NCT05790889 is currently recruiting now. Last updated 7 March 2025.

Last reviewed 2025-03-07 · How we verify

NCT05790889

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.

Recruiting now Phase 1, PHASE2 Last updated 7 March 2025

What this trial tests

Phase 1, PHASE2 trial testing Rabies vaccine in Malaria,Falciparum in 480 participants. Currently enrolling.

Timeline

3 April 2023

Primary endpoint
30 May 2026

30 May 2026

Quick facts

Lead sponsor	University of Oxford
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	480
Start date	3 April 2023
Primary completion	30 May 2026
Estimated completion	30 May 2026
Sites	1 location across Burkina Faso

Drugs / interventions tested

Rabies vaccine — full drug profile →
RH5.1 10μg adjuvated with 50μg Matrix-M — full drug profile →
RH5.2 5μg adjuvated with 50μg Matrix-M — full drug profile →

Conditions studied

Malaria,Falciparum — all drugs for Malaria,Falciparum →

Sponsor

University of Oxford

Who can join

Adults 5 Months to 17 Months, any sex, with Malaria,Falciparum. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase IIb randomised controlled trial of the safety, immunogenicity and efficacy of the blood-stage malaria vaccine candidates RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in infants aged 5-17 months in Burkina Faso

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial.
Silk SE, Kalinga WF, Salkeld J, Mtaka IM, et al · · 2024 · cited 34× · PMID 38880111 · DOI 10.1016/s1473-3099(24)00312-8
Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children.
Natama HM, Salkeld J, Somé A, Soremekun S, et al · · 2025 · cited 26× · PMID 39672183 · DOI 10.1016/s1473-3099(24)00752-7
Vaccines and monoclonal antibodies: new tools for malaria control.
Miura K, Flores-Garcia Y, Long CA, Zavala F. · · 2024 · cited 24× · PMID 38656211 · DOI 10.1128/cmr.00071-23
Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype.
Barrett JR, Pipini D, Wright ND, Cooper AJR, et al · · 2024 · cited 22× · PMID 39059380 · DOI 10.1016/j.cell.2024.06.015
Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies.
King LDW, Pulido D, Barrett JR, Davies H, et al · · 2024 · cited 16× · PMID 39019011 · DOI 10.1016/j.xcrm.2024.101654
The Need for Novel Asexual Blood-Stage Malaria Vaccine Candidates for <i>Plasmodium falciparum</i>.
Takashima E, Otsuki H, Morita M, Ito D, et al · · 2024 · cited 15× · PMID 38254700 · DOI 10.3390/biom14010100
Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5.
Wang LT, Cooper AJR, Farrell B, Miura K, et al · · 2024 · cited 11× · PMID 39059381 · DOI 10.1016/j.cell.2024.06.037
A new landscape for malaria vaccine development.
Laurenson AJ, Laurens MB. · · 2024 · cited 6× · PMID 38935630 · DOI 10.1371/journal.ppat.1012309

Verify or expand the search:

Other trials of Rabies vaccine

Trials testing the same drug.

NCT07055893 — Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen · Phase 3 · not yet recruiting
NCT07345208 — Safety and Immunogenicity of ID vs IM Rabies Vaccine · Phase 2, PHASE3 · not yet recruiting
NCT03961555 — Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies · Phase 2 · completed
NCT03276962 — Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules · Phase 2 · completed
NCT02374814 — Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis · Phase 4 · completed

Other recruiting trials for Malaria,Falciparum

Currently open trials in the same condition.

NCT06618885 — Safety and Immunogenicity of SUM-101 Malaria Vaccine in Children and Infants Living in Burkina Faso · Phase 1 · active not recruiting
NCT07009847 — An Observational Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria Vaccine · recruiting
NCT06524336 — Host Immune Dynamics Following Seasonal Malaria Chemoprevention in African Children · active not recruiting
NCT05978037 — A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines · Phase 1, PHASE2 · active not recruiting
NCT05676645 — Pharmacokinetics of Antimalarials in Breastfeeding Ugandan Mother-infant Pairs · active not recruiting

Other University of Oxford trials

Trials by the same sponsor.

NCT05380388 — A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) · Phase 2 · not yet recruiting
NCT07470424 — A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults · Phase 1 · not yet recruiting
NCT07345910 — Environment, Pathogens, and Host Interactions in Melioidosis · not yet recruiting
NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE · Phase 3 · not yet recruiting
NCT07460401 — 'Do Patient Characteristics Associate With Poor Outcome With Femoral Acetabular Impingement Syndrome (FAIS) Following Ph · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05790889 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oxford
Last refreshed: 7 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05790889.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing